
















Type of <i>BRAF</i> mutation	Type of tumor	<i>BRAF</i> mutant protein	Tumor cells sensitivity to Vemurafenib treatment
Biallelic p.V600D and p.K601del 	Homogeneous tumor: one clone 	$BRAF^{V600D}$ and $BRAF^{K601del}$ 	 Vemurafenib treatment Predicted sensitivity: - <i>In vitro</i> data for $BRAF^{V600D}$ and no data indicating that $BRAF^{K601del}$ could be a resistance mutation
Biclonal p.K601del  	Heterogeneous tumor: two clones 	 $BRAF^{K601del}$  $BRAF^{V600D}$	 Vemurafenib treatment ?  Vemurafenib treatment Predicted sensitivity: - <i>In vitro</i> data
Monoallelic p.V600DK601del 	Homogeneous tumor: one clone 	$BRAF^{V600DK601del}$ 	 Vemurafenib treatment ?

■ V600D
■ K601del